Reply to: “Predictors of sorafenib benefit in patients with hepatocellular carcinoma”

Jordi Bruix, Ann Lii Cheng, Josep Llovet

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish
Pages (from-to)620-621
Number of pages2
JournalJournal of Hepatology
Volume68
Issue number3
DOIs
StatePublished - Mar 2018

Cite this